EX-10.12





 Exhibit 10.12 

 
 



 
 August 24th, 2020 

Ms. Jennifer Bush 
 Private &
Confidential 
  

	Re:	 Employment Offer Letter 



Dear Jennifer, 
 On behalf of Artiva Biotherapeutics, Inc. (the
“Company”), I am pleased to offer you employment under the terms set forth in this offer letter agreement (this “Agreement”). These employment terms will be effective as of your start date, September 16th, 2020. 
 Employment Position; Duties. You will be employed as the Company’s Executive Vice
President, General Counsel, Corporate Secretary and Compliance Officer, reporting to the Company’s President & CEO. You will have those duties and responsibilities as are customary for these positions and as may be directed by the
Company. You will work from the corporate office in San Diego and your position may require business travel. During your employment, you will devote your full-time best efforts to the business of the Company. 

1. Base Salary; Employee Benefits and Business Expenses. 

(a) Base Salary. Your initial base salary will be paid at the annual rate of $350,000.00 less standard payroll deductions and tax
withholdings. Your base salary will be paid on the Company’s normal payroll schedule. As an exempt salaried employee, you will be required to work the Company’s normal business hours, and such additional time as appropriate for your work
assignments and position. You will not be eligible for extra payment under the overtime laws. 
 (b) Employee Benefits. As a regular
full-time employee, you will be eligible to participate in the Company’s standard employee benefits (pursuant to the terms and conditions of the benefit plans and applicable policies), as they may be terminated or changed from time to time
within the Company’s discretion. 
 (c) Business Expenses. Your legitimate and documented business expenses will be reimbursed by
the Company as provided under its business expense reimbursement policies. 
 2. Annual Bonus. In addition to base salary, you will be
eligible to earn discretionary incentive compensation at an annual target amount of thirty percent (30%) of your base salary in effect during the bonus year. With respect to the annual incentive compensation program, the Company’s
executive team will evaluate and recommend specific annual individual and corporate performance 

  

			
	Artiva Biotherapeutics, Inc.	  	4747 Executive Drive #1150, San Diego CA 92121














 
targets, metrics and/or management-by-objectives (“MBOs”), to be finalized and approved by
Company’s Board of Directors (the “Board”), as part of its annual compensation review process. Annual bonuses are paid on an annual basis, after the close of the fiscal year and after determination by the Board of (a) the
level of achievement of the applicable individual and corporate performance targets, metrics and/or MBOs, and (b) the amount of the annual incentive compensation earned by you (if any). No amount of annual incentive compensation is guaranteed
and, in addition to the other conditions for earning such compensation, you must remain an employee in good standing of the Company on the scheduled annual incentive compensation payment date in order to be eligible for any annual incentive
compensation. This annual incentive compensation program will be the only incentive compensation, commissions, or other bonus program that will apply to you. 

3. Equity Award. Upon joining the Company, and subject to approval by the Company’s Board of Directors, you will be eligible to
receive a stock option to purchase 100,000 shares of common stock. The purchase price per share will be equal to the fair market value of the Company’s common stock on the date of grant. Twenty-five percent (25%) of the shares subject to the
option will vest on the one year anniversary of the vesting commencement date, December 5th, 2019, and the remainder will vest in equal monthly installments thereafter over the next thirty-six (36) months, subject to your continued service with the Company. The terms of the option will be governed by the Company’s 2020 Equity Incentive Plan (the “Plan”) and an option
award agreement between you and the Company. 
 4. Compliance with Confidentiality Agreement and Company Policies. As a condition of
employment, you shall sign and comply with the Company’s standard form of Employee Confidential Information and Invention Assignment Agreement (the “Confidentiality Agreement”). The Confidentiality Agreement shall be deemed
fully incorporated into this Agreement by reference. You are also required to sign and certify there is no debarment. 
 5. Protection of
Third Party Information and Outside Activities. 
 (a) Third Party Information. In your work for the Company, you will be expected
not to make any unauthorized use or disclosure of any confidential information or materials, including trade secrets, of any former employer or other third party; and not to violate any lawful agreement that you may have with any third party. By
signing this Agreement, you represent that you are able to perform your job duties within these guidelines, and you are not in unauthorized possession or control of any confidential documents, information, or other property of any former employer.
In addition, you represent that you have disclosed to the Company in writing any agreement you may have with any third party (e.g., a former employer) that may limit your ability to perform your duties to the Company or that could present a conflict
of interest with the Company, including but not limited to disclosure (and a copy) of any contractual restrictions on solicitations or competitive activities. 

(b) Outside Activities. During your employment by the Company, you may engage in civic and not-for-profit activities so long as such activities do not interfere with the performance of your duties hereunder or present a conflict of interest with the Company or its Affiliates (as defined in the
Plan). Subject to the restrictions set forth herein, and only with prior written disclosure to and written consent of the Board, you may engage in other types of business or public activities. The Board may withdraw such consent, if the Board
determines, in its sole discretion, that such activities compromise or threaten to compromise the business interests of the Company or its Affiliates or conflict with your duties to the Company. 












 (c) Non-Competition. During your employment
by the Company, you will not, without the express written consent of the Board, directly or indirectly serve as an officer, director, stockholder, employee, partner, proprietor, investor, joint venturer, associate, representative or consultant of
any person or entity engaged in, or planning or preparing to engage in, business activity competitive with any line of business engaged in (or planned to be engaged in) by the Company or its Affiliates; provided, however, that you may purchase or
otherwise acquire up to (but not more than) one percent (1%) of any class of securities of any enterprise (without participating in the activities of such enterprise) if such securities are listed on any national or regional securities exchange. In
addition, you will be subject to certain restrictions (including restrictions continuing after your employment ends) under the terms of your Confidentiality Agreement. 

6. At-Will Employment Relationship. Your employment relationship with the Company is employment at-will. Accordingly, you may terminate your employment with the Company at any time and for any reason whatsoever simply by notifying the Company; and the Company may terminate your employment at any time with or
without Cause (as defined below) or prior notice. In addition, the Company retains the discretion to modify your other employment terms from time to time, including but not limited to your position, duties, reporting relationship, work location,
compensation (including base salary and incentive compensation terms), and benefits. 
 7. Severance. 

(a) Severance for Qualifying Termination. If (i) your employment is terminated by the Company without Cause, other than due to your
death or disability, or you terminate your employment for Good Reason (as defined in the Plan) and (ii) you satisfy the Release Requirement (defined below), then you will receive the Severance Payments (defined below) as your sole severance
benefits, and you will not be eligible for severance benefits under any other policy, plan or agreement. Specifically, you will receive severance pay in the form of continuation of your final monthly base salary for six (6) months, less
standard payroll deductions and tax withholdings (the “Severance Payments”). Subject to Section 7(e), the Severance Payments will be paid in equal installments on the Company’s regular payroll schedule in effect following
your termination date, with such payments to begin on the first regular payroll date following the Release Effective Date (as defined below). If the Severance Payments do not commence with the first regular payroll date following your termination
date because the Release Effective Date is later than such first payroll date, the first installment of the Severance Payments you receive will be a “catch up” payment in the total amount of the Severance Payments you would have received
through such payroll date if such payments had begun with the first payroll date after your termination date. 
 (b) Release Requirement.
To be eligible for the Severance Payments pursuant to Section 7(a) above you must satisfy the following release requirement (the “Release Requirement”): return to the Company a signed and dated general release of all known
and unknown claims in a separation agreement acceptable to the Company (the “Release and Waiver”) within the applicable deadline set forth therein, but in no event later than forty-five (45) calendar days following your
termination date, and permit the Release and Waiver to become effective and irrevocable in accordance with its terms (such effective date of the Release and Waiver, the “Release Effective Date”). No Severance Payments will be paid
hereunder prior to such Release Effective Date. You may be required by the separation agreement to provide reasonable transitional services as a condition of payment of Severance Payments. 












 (c) Definition of Cause. For purposes of this Agreement, “Cause”
means the occurrence of any one or more of the following: (i) your conviction of, or plea of no contest, or commission of any felony or any crime involving fraud, embezzlement, dishonesty or moral turpitude; (ii) your attempted commission
of, or participation in, a fraud, embezzlement or act of dishonesty (or an attempted fraud or act of dishonesty) that results in (or could result in) material harm to the Company, including but not limited to material harm to reputational interests;
(iii) your violation of a fiduciary duty or duty of loyalty owed to the Company; (iv) your material breach of any contract or agreement between you and the Company, or any material Company policies that are disclosed or otherwise made
available in writing to you prior to such breach; (v) persistent neglect of your job duties, which is not cured within fifteen (15) calendar days after you are provided written notice by the Company (provided, that such written notice and
opportunity to cure are not required if your performance or neglect is not reasonably susceptible to being cured); or (vi) your gross misconduct or material failure to comply with a reasonable written instruction of the Company. 

(d) Other. You will not be eligible for any Severance Payments under any circumstances other than those described herein, including
circumstances in which your employment is terminated for Cause, you terminate your employment for any reason, or your employment terminates due to your death or disability. In addition, if you materially breach any continuing obligations to the
Company (including, but not limited to, any material breach of this Agreement or any material breach of the Confidentiality Agreement) during the period of time that you are receiving any Severance Payments, you will forfeit your entitlement to any
then unpaid Severance Payments, and the Company’s obligation to continue to pay or provide such Severance Payments will immediately terminate as of the date of your material breach. 

(e) IRS Code Section 409A. All payments provided hereunder are intended to constitute separate payments for purposes
of Treasury Regulation Section 1.409A-2(b)(2). If the Company determines that any benefits provided under this Agreement constitute “deferred compensation” under Section 409A of the
Internal Revenue Code of 1986 as amended (“Section 409A”), such benefits will not commence in connection with your termination of employment unless such termination also qualifies as a “separation from
service” with the Company within the meaning of Treasury Regulation Section 1.409A-1(h) (without regard to any permissible alternative definition thereunder) (“Separation from
Service”). If the Company determines that any benefits provided under this Agreement constitute “deferred compensation” under Section 409A and you are a “specified employee” of the Company or any affiliate (or any
successor entity thereto) within the meaning of Section 409A(a)(2)(B)(i) of the Code on the date of your Separation from Service, then the payment of any such benefits shall be delayed until the earlier of (i) the date that is six
(6) months and one (1) day after the date of your Separation from Service, or (ii) the date of your death (such date, the “Delayed Payment Date”), and the Company (or the successor entity thereto, as applicable) shall
(A) pay to you a lump sum amount equal to the sum of the benefit payments that otherwise would have been paid to you on or before the Delayed Payment Date, without any adjustment on account of such delay, and (B) continue the benefit
payments in accordance with any applicable payment schedules set forth for the balance of the period specified herein. In addition to the above, to the extent required to comply with Section 409A and the applicable regulations and guidance
issued thereunder, if the applicable deadline for you to execute (and not revoke) the applicable Release and Waiver spans two (2) calendar years, your Severance Payments shall commence to be paid in installments on the first regularly scheduled
payroll date that occurs in the second calendar year after the Release Effective Date of the Release and Waiver. 












 8. Section 280G; Limitations on Payment. 

(a) If any payment or benefit you will or may receive from the Company or otherwise (a “280G Payment”) would
(i) any constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise
Tax”), then any such 280G Payment provided pursuant to this Agreement (a “Payment”) shall be equal to the Reduced Amount. The “Reduced Amount” shall be either (x) the largest portion of the Payment
that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by
clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in your receipt, on an
after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding
sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction shall occur in the manner (the “Reduction Method”) that results in the greatest economic benefit for you. If more
than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the “Pro Rata Reduction Method”). 

(b) Notwithstanding any provision of Section 8(a) to the contrary, if the Reduction Method or the Pro Rata Reduction Method would
result in any portion of the Payment being subject to taxes pursuant to Section 409A that would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be,
shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows: (i) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for you as determined on
an after-tax basis; (ii) as a second priority, Payments that are contingent on future events (e.g., being terminated without Cause), shall be reduced (or eliminated) before Payments that are not
contingent on future events; and (iii) as a third priority, Payments that are “deferred compensation” within the meaning of Section 409A shall be reduced (or eliminated) before Payments that are not deferred compensation within
the meaning of Section 409A. 
 (c) Unless you and the Company agree on an alternative accounting firm or law firm, the
accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the Change of Control transaction shall perform the foregoing calculations. If the accounting firm so engaged by the Company is
serving as accountant or auditor for the individual, entity or group effecting the Change in Control transaction, the Company shall appoint a nationally recognized accounting or law firm to make the determinations required by this Section 8.
The Company shall bear all expenses with respect to the determinations by such accounting or law firm required to be made hereunder. The Company shall use commercially reasonable efforts to cause the accounting or law firm engaged to make the
determinations hereunder to provide its calculations, together with detailed supporting documentation, to you and the Company within fifteen (15) calendar days after the date on which your right to a 280G Payment becomes reasonably likely to
occur (if requested at that time by you or the Company) or such other time as requested by you or the Company. 
 (d) If you receive a
Payment for which the Reduced Amount was determined pursuant to clause (x) of Section 8(a) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, you agree to promptly return
to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of Section 8(a)) so that no portion of the remaining 












 
Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) of Section 8(a), you shall have no obligation to return any
portion of the Payment pursuant to the preceding sentence. 
 9. Dispute Resolution. To ensure the rapid and economical resolution of
disputes that may arise in connection with your employment with the Company, you and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating
to the enforcement, breach, performance, or interpretation of this Agreement, your employment with the Company, or the termination of your employment with the Company, will be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. §1-16, and to the fullest extent permitted by law, by final, binding and confidential arbitration conducted by JAMS, Inc. (“JAMS”) or its successors by a single arbitrator. The arbitration will
be held in San Diego, California, or such other location as then-agreed by the parties. Both you and the Company acknowledge that by agreeing to this arbitration procedure, you each waive the right to resolve any such dispute through a trial
by jury or judge or administrative proceeding. 
 Any such arbitration proceeding will be governed by JAMS’ then applicable rules and
procedures for employment disputes, which will be provided to you upon request. In any such proceeding, the arbitrator shall (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would
otherwise be permitted by law; and (b) issue a written arbitration decision including the arbitrator’s essential findings and conclusions and a statement of the award. You and the Company shall be entitled to all rights and remedies that
either would be entitled to pursue in a court of law. Nothing in this Agreement is intended to prevent either the Company or you from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration
pursuant to applicable law. The Company shall pay all filing fees in excess of those which would be required if the dispute were decided in a court of law and shall pay the arbitrator’s fees and any other fees or costs unique to arbitration.
Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. 

10. General. This Agreement, along with the Confidentiality Agreement, forms the complete and exclusive statement of your agreement with
the Company regarding the subject matter hereof. It supersedes and replaces any other agreements or promises made to you by anyone concerning your employment compensation, benefits and/or terms, whether oral or written. This Agreement may not be
amended or modified except by a written modification signed by you and a duly authorized officer of the Company, with the exception of those changes expressly reserved to the Company’s discretion in this Agreement. This Agreement is governed by
the laws of the state of California, without reference to conflicts of law principles, and it is intended to bind and inure to the benefit of and be enforceable by the Company and its successors and assigns. If any provision of this Agreement shall
be held invalid or unenforceable in any respect, such invalidity or unenforceability shall not affect the other provisions of this Agreement, and such provision will be reformed, construed and enforced so as to render it valid and enforceable
consistent with the general intent of the parties insofar as possible under applicable law. With respect to the enforcement of this Agreement, no waiver of any right hereunder shall be effective unless it is in writing. Any ambiguity in this
Agreement shall not be construed against either party as the drafter. This Agreement may be executed in counterparts which shall be deemed to be part of one original, and facsimile signatures shall be equivalent to original signatures. 












 To confirm your terms of continuing employment, please sign and date this Agreement and the Confidentiality
Agreement and return the fully signed documents to me. Please let me know if you have any questions. 
 Sincerely, 

 

			
	ARTIVA BIOTHERAPEUTICS, INC.
		
	By:	 	 /s/ Thomas J. Farrell

		 	Thomas J. Farrell,
		 	President and Chief Executive Officer

  

							
	Reviewed, Understood, and Accepted:	 		 		 	
				
	 /s/ Jennifer K. Bush, J.D.
	 		 		 	 August 27, 2020

	Jennifer K. Bush, J.D.	 		 		 	Date














 



 
  

 April 7, 2021 

Jennifer Bush 
 Re: Amendment No. 1 to Employment
Offer Letter 
 Dear Jennifer, 
 This letter (this
“Amendment”) amends your Employment Offer Letter with Artiva Biotherapeutics, Inc. (the “Company”), dated August 24, 2020 (the “Offer Letter”), and is effective as of (and is conditioned upon)
the closing of the first underwritten public offering of the equity securities of the Company pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). All capitalized terms
not otherwise defined herein shall have the same meanings as set forth in the Offer Letter. 
 In consideration of the mutual promises, covenants and
conditions hereinafter set forth, and other consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto agree as follows: 
  

	 	1.	 Amendments 


  

	 	a.	 The first sentence of the Section entitled “Employment Position; Duties” is hereby amended and
restated to read as follows: 


 “You will continue to be employed as the Company’s Executive Vice President,
Chief Legal & People Officer, reporting to the Company’s President & CEO.” 
  

	 	b.	 The first sentence of Section 1(a) of the Offer Letter is hereby amended and restated to read as follows:



 “Your base salary will be paid at the annual rate of $388,600, less standard payroll deductions and tax
withholdings.” 
  

	 	c.	 The first sentence of Section 2 of the Offer Letter is hereby amended and restated to read as follows:



 “In addition to your base salary, you will be eligible to earn discretionary incentive compensation at an annual
target amount of forty percent (40%) of your base salary in effect during the bonus year (the “Annual Bonus”).” 
  

	 	d.	 Section 7 of the Offer Letter is hereby amended and restated in its entirety to read as
follows:     


 7. Severance 

(a) Severance upon Termination without Cause or Resignation with Good Reason. If (i) your employment is terminated by the
Company without Cause (as defined in the Company’s 2020 Equity Incentive Plan, or any successor or replacement plan, the “Plan”), other than due to your death or disability, or you terminate your employment with Good Reason (as
defined in the Plan), (ii) you satisfy the Release Requirement (defined below), and (iii) comply with your obligations under the Confidentiality Agreement, then you will receive the following “Severance Benefits”: (A)
You will receive severance pay in the form of continuation of your final monthly base salary for a period of nine (9) months following your termination date, less standard payroll deductions and tax withholdings (the “Severance
Payments”). Subject to Section 7(e), the Severance Payments will be paid in equal installments on the Company’s regular payroll schedule in effect following your termination date, with such payments to begin


  
  

			
	Artiva Biotherapeutics, Inc.	  	4747 Executive Drive #1150, San Diego Ca 92121















 



 
  

 
on the first regular payroll date following the Release Effective Date (as defined below). If the Severance Payments do not commence with the first regular payroll date following your termination
date because the Release Effective Date is later than such first payroll date, the first installment of the Severance Payments you receive will be a “catch up” payment in the total amount of the Severance Payments you would have received
through such payroll date if such payments had begun with the first payroll date after your termination date; (B) In addition, if you timely elect continued coverage under COBRA, the Company will pay the COBRA premiums for you and your
eligible dependents until the earlier of either: (i) a period ending nine (9) months following your termination date or, (ii) the date on which you are no longer eligible for COBRA coverage (such period, the “COBRA Payment
Period”). Notwithstanding the foregoing, if the Company determines, in its sole discretion, that the Company cannot provide the COBRA premium benefits without potentially incurring financial costs or penalties under applicable law
(including, without limitation, Section 2716 of the Public Health Service Act), the Company shall in lieu thereof pay you a taxable cash amount, which payment shall be made regardless of whether you or your qualifying family members elect COBRA
continuation coverage (the “Health Care Benefit Payment”). The Health Care Benefit Payment shall be paid in installments on the same schedule that the COBRA premiums would otherwise have been paid to the insurer. The Health Care
Benefit Payment shall be equal to the amount that the Company otherwise would have paid for COBRA insurance premiums (which amount shall be calculated based on the premium for the first month of coverage), and shall be paid until the expiration of
the COBRA Payment Period. For purposes of this Agreement, (i) references to COBRA shall be deemed to refer also to analogous provisions of state law and (ii) any applicable insurance premiums that are paid by the Company shall not include
any amounts payable by you under an Internal Revenue Code Section 125 health care reimbursement plan, which amounts, if any, are your sole responsibility; and (C) The vesting and exercisability of all outstanding and unvested equity
awards covering the Company’s common stock that are held by you as of immediately prior to the termination date, to the extent such equity awards would otherwise have vested solely conditioned on your continued services with the Company, shall
accelerate vesting in accordance with their applicable vesting schedules as if you had completed an additional three (3) months of service with the Company as of the termination date. 

(b) Severance upon Termination without Cause or Resignation with Good Reason in Connection with a Change of Control. If
(i) your employment is terminated by the Company without Cause (as defined in the Plan), other than due to your death or disability, or you terminate your employment with Good Reason (as defined in the Plan), in each case within a period
commencing three (3) months before, or twelve (12) months after a Change of Control (as defined in the Plan), (ii) you satisfy the Release Requirement (defined below), and (iii) comply with your obligations under the Confidentiality
Agreement, then you will receive the following “Change of Control Severance Benefits”: (A) You will receive severance pay in the form of continuation of your final monthly base salary for a period of twelve (12) months
following your termination date, less standard payroll deductions and tax withholdings (the “Change of Control Severance Payments”). Subject to Section 7(e), the Severance Payments will be paid in equal installments on
the Company’s regular payroll schedule in effect following your termination date, with such payments to begin on the first regular payroll date following the Release Effective Date (as defined below). If the Severance Payments do not commence
with the first regular payroll date following your termination date because the Release Effective Date is later than such first payroll date, the first installment of the Severance Payments you receive will be a “catch up” payment in the
total amount of the Severance Payments you would have received through such payroll date if such payments had begun with the first payroll date after your termination date; (B) In addition, if you timely elect continued coverage under
COBRA, the Company will pay the COBRA premiums for you and your eligible dependents until the earlier of either: (i) a period ending twelve (12) months following your termination date or, (ii) the date on which you are no longer
eligible for COBRA coverage 

  
  

			
	Artiva Biotherapeutics, Inc.	  	4747 Executive Drive #1150, San Diego Ca 92121















 



 
  

 
(such period, the “COBRA Payment Period”). Notwithstanding the foregoing, if the Company determines, in its sole discretion, that the Company cannot provide the COBRA premium
benefits without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company shall in lieu thereof pay you a taxable cash amount, which
payment shall be made regardless of whether you or your qualifying family members elect COBRA continuation coverage (the “Health Care Benefit Payment”). The Health Care Benefit Payment shall be paid in installments on the same
schedule that the COBRA premiums would otherwise have been paid to the insurer. The Health Care Benefit Payment shall be equal to the amount that the Company otherwise would have paid for COBRA insurance premiums (which amount shall be calculated
based on the premium for the first month of coverage), and shall be paid until the expiration of the COBRA Payment Period. For purposes of this Agreement, (i) references to COBRA shall be deemed to refer also to analogous provisions of state
law and (ii) any applicable insurance premiums that are paid by the Company shall not include any amounts payable by you under an Internal Revenue Code Section 125 health care reimbursement plan, which amounts, if any, are your sole
responsibility; (C) In addition, you will receive your full target Annual Bonus for the fiscal year in which your employment terminates, payable on the first regular payroll date following the Release Effective Date, provided that the
Release Requirement has been satisfied; and (D) Effective as of the later of the termination date or the effective date of the Change of Control, the vesting and exercisability of all outstanding and unvested equity awards covering the
Company’s common stock that are held by you as of immediately prior to such date, to the extent such equity awards would otherwise have vested solely conditioned on your continued services with the Company, shall accelerate vesting in full. For
the avoidance of doubt, in no event shall you be entitled to benefits under both Section 7(a) and this Section 7(b). If you are eligible for benefits under both Section 7(a) and this Section 7(b), you shall receive the benefits
set forth in this Section 7(b) and such benefits shall be reduced by any benefits previously provided to you under Section 7(a). 

(c) Release Requirement. To be eligible for the Severance Benefits and Change pursuant to Section 7(a) and the Change of Control
Severance Benefits pursuant to Section 7(b) above, you must satisfy the following release requirement (the “Release Requirement”): You must timely execute and return to the Company a signed and dated general release of all
known and unknown claims in a separation agreement acceptable to the Company (the “Release and Waiver”) within the applicable deadline set forth therein, but in no event later than forty-five (45) calendar days following your
termination date, and permit the Release and Waiver to become effective and irrevocable in accordance with its terms (such effective date of the Release and Waiver, the “Release Effective Date”). No Severance Benefits or Change of
Control Severance Benefits will be paid or provided hereunder prior to such Release Effective Date. You may be required by the separation agreement to provide reasonable transitional services as a condition to receiving the Severance Benefits and/or
the Change of Control Severance Benefits. 
 (d) Other. You will not be eligible for any Severance Benefits or Change of Control
Severance Benefits under any circumstances other than those described herein, including circumstances in which your employment is terminated for Cause, you terminate your employment for any reason other than Good Reason, or your employment
terminates due to your death or disability. In addition, if you materially breach any continuing obligations to the Company (including, but not limited to, any material breach of this Agreement or any material breach of the Confidentiality
Agreement) during the period of time that you are receiving any Severance Benefits or Change of Control Severance Benefits, as applicable, you will forfeit your entitlement to any then unpaid Severance Benefits and/or Change of Control Severance
Benefits, as applicable, and the Company’s obligation to continue to pay or provide such Severance Benefits and Change of Control Severance Benefits will immediately terminate as of the date of your material breach and you will be required to
return to the Company any Severance Benefits and Change of Control Severance Benefits already provided to you. 

  
  

			
	Artiva Biotherapeutics, Inc.	  	4747 Executive Drive #1150, San Diego Ca 92121















 



 
  

 (e) IRS Code Section 409A. All payments provided hereunder are
intended to constitute separate payments for purposes of Treasury Regulation Section 1.409A-2(b)(2). If the Company determines that any benefits provided under this Agreement constitute “deferred
compensation” under Section 409A of the Internal Revenue Code of 1986 as amended (“Section 409A”), such benefits will not commence in connection with your termination of employment unless such
termination also qualifies as a “separation from service” with the Company within the meaning of Treasury Regulation Section 1.409A- 1(h) (without regard to any permissible alternative definition thereunder) (“Separation from
Service”). If the Company determines that any benefits provided under this Agreement constitute “deferred compensation” under Section 409A and you are a “specified employee” of the Company or any affiliate (or any
successor entity thereto) within the meaning of Section 409A(a)(2)(B)(i) of the Code on the date of your Separation from Service, then the payment of any such benefits shall be delayed until the earlier of (i) the date that is six
(6) months and one (1) day after the date of your Separation from Service, or (ii) the date of your death (such date, the “Delayed Payment Date”), and the Company (or the successor entity thereto, as applicable) shall
(A) pay to you a lump sum amount equal to the sum of the benefit payments that otherwise would have been paid to you on or before the Delayed Payment Date, without any adjustment on account of such delay, and (B) continue the benefit
payments in accordance with any applicable payment schedules set forth for the balance of the period specified herein. In addition to the above, to the extent required to comply with Section 409A and the applicable regulations and guidance
issued thereunder, if the applicable deadline for you to execute (and not revoke) the applicable Release and Waiver spans two (2) calendar years, your Severance Benefits and/or Change of Control Severance Benefits shall commence to be paid in
installments on the first regularly scheduled payroll date that follows the effective date of the Release and Waiver and which also occurs during the second permitted calendar year for returning the effective Release and Waiver. 

2. Miscellaneous. Except as expressly amended hereby, the Offer Letter, as amended by this Amendment, shall continue in full force and effect in
accordance with its terms. This Amendment is governed by the laws of the state of California, without reference to conflicts of law principles. This Amendment may be executed in counterparts, each of which will be deemed an original, but both of
which together will constitute one and the same instrument. Counterparts may be delivered via electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other
applicable law) or other transmission method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

Please acknowledge your agreement with this Amendment by signing below. 

Sincerely, 
  

			
	ARTIVA BIOTHERAPEUTICS, INC.


 
			
		
	By:	 	 /s/ Fred Aslan, MD

	Name: Fred Aslan, MD
	Title: Chief Executive Officer & President
	
	Acknowledged and Agreed:
	
	 /s/ Jennifer Bush

	Jennifer Bush



  
  

			
	Artiva Biotherapeutics, Inc.	  	4747 Executive Drive #1150, San Diego Ca 92121